Last reviewed · How we verify
Xiyanping injection plus western therapy
Xiyanping injection plus western therapy is a Small molecule drug developed by Jiangxi Qingfeng Pharmaceutical Co. Ltd.. It is currently in Phase 1 development.
Xiyanping injection has been studied in combination with western therapy for the treatment of Hand, Foot and Mouth Disease. The mechanism of action of Xiyanping injection is currently unknown.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Xiyanping injection plus western therapy |
|---|---|
| Sponsor | Jiangxi Qingfeng Pharmaceutical Co. Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Effectiveness and Safety of Chinese Medicine to Treat Hand, Foot, and Mouth Disease (NA)
- A Clinical Trial to Evaluate the Effectiveness and Safety of Xiyanping Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xiyanping injection plus western therapy CI brief — competitive landscape report
- Xiyanping injection plus western therapy updates RSS · CI watch RSS
- Jiangxi Qingfeng Pharmaceutical Co. Ltd. portfolio CI
Frequently asked questions about Xiyanping injection plus western therapy
What is Xiyanping injection plus western therapy?
Who makes Xiyanping injection plus western therapy?
What development phase is Xiyanping injection plus western therapy in?
Related
- Manufacturer: Jiangxi Qingfeng Pharmaceutical Co. Ltd. — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing